^
2ms
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire)
"Kairos Pharma Ltd...announces a groundbreaking collaboration with PreCheck Health Services Inc...The partnership focuses on the development of companion biomarkers for Kairos Pharma’s cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma’s Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105....Kairos Pharma and PreCheck Health Services will utilize advanced molecular diagnostics to corroborate and further develop biomarkers previously identified in a Phase 2 clinical trial. These biomarkers are designed to predict patient responses to ENV105 prior to treatment, offering a more personalized approach to cancer care."
Licensing / partnership
|
carotuximab IV (ENV-105)
9ms
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov)
P2, N=100, Recruiting, Edwin Posadas, MD | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Oct 2026 --> Jan 2027
Trial completion date • Trial primary completion date • Metastases
|
Erleada (apalutamide) • carotuximab IV (ENV-105)
1year
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Karen Reckamp, MD, MS | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib) • carotuximab IV (ENV-105)
1year
Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis. (PubMed, Clin Cancer Res)
Our data unveil a tumor-promoting function of ENG in MPNSTs and support the use of this protein as a novel biomarker and a promising therapeutic target for this disease.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • ENG (Endoglin)
|
carotuximab IV (ENV-105)
1year
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial. (PubMed, Commun Med (Lond))
Single-agent TRC105 lacks activity in bevacizumab-refractory GBM, possibly secondary to upregulated VEGF-A expression. Meaningful mOS in bevacizumab+TRC105 cohort warrants further trials to investigate efficacy of combination therapy.
P2 data • Journal
|
ENG (Endoglin)
|
VEGFA elevation • VEGFA expression
|
Avastin (bevacizumab) • temozolomide • carotuximab IV (ENV-105)
over1year
Trial completion • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)
over1year
Endoglin and squamous cell carcinomas. (PubMed, Front Med (Lausanne))
On the functional level, endoglin, both in a ligand dependent and independent manner, did not influence proliferation or migration of the SCC cells. In conclusion, these data show endoglin expression on individual cells in the tumor nests in SCCs and a role for (soluble) endoglin in paracrine signaling, without directly affecting proliferation or migration in an autocrine manner.
Journal
|
ALK1 (Activin A Receptor Like Type 1) • TGFB1 (Transforming Growth Factor Beta 1) • ENG (Endoglin) • SMAD1 (SMAD Family Member 1)
|
ENG elevation
|
carotuximab IV (ENV-105)
over1year
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. (PubMed, Breast Cancer Res Treat)
Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.
P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ENG (Endoglin)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)
almost2years
Neuroblastoma Tumor-Associated Mesenchymal Stromal Cells Regulate the Cytolytic Functions of NK Cells. (PubMed, Cancers (Basel))
Inhibitors of the soluble immunosuppressive factors L-kynurenine and prostaglandin E2 efficiently counteract this latter effect. Our data highlight the presence of phenotypically heterogeneous NB-TA-MSC displaying potent immunoregulatory properties towards NK cells, whose inhibition could be mandatory to improve the antitumor efficacy of targeted immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker • Stroma
|
PD-L1 (Programmed death ligand 1) • MCAM (Melanoma Cell Adhesion Molecule) • THY1 (Thy-1 membrane glycoprotein) • ENG (Endoglin) • ITGB1 (Integrin Subunit Beta 1)
|
carotuximab IV (ENV-105)
almost2years
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Karen Reckamp, MD, MS | Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Dec 2023
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib) • carotuximab IV (ENV-105)
2years
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Karen Reckamp, MD, MS | Trial completion date: Oct 2025 --> Jan 2026 | Initiation date: Aug 2022 --> Jan 2023 | Trial primary completion date: Oct 2024 --> Jan 2025
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib) • carotuximab IV (ENV-105)
over2years
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). (PubMed, Neurooncol Adv)
Quality of life scores were similar for both treatment arms. TRC105 in combination with bevacizumab was well tolerated in patients with recurrent GBM, but no difference in efficacy was observed compared to bevacizumab monotherapy.
P2 data • Journal
|
ENG (Endoglin)
|
Avastin (bevacizumab) • carotuximab IV (ENV-105)
over2years
New P1 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib) • carotuximab IV (ENV-105)
almost3years
Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=14, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)
3years
Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model. (PubMed, Onco Targets Ther)
Finally, genetic deletion of endoglin from collagen 1a1 expressing cells also did not affect the growth of the mouse KPC tumors. Our results show that although endoglin is highly expressed on PDAC-CAFs and signaling is efficiently inhibited by TRC105, this does not result in decreased tumor growth in the KPC model for pancreatic cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • ENG (Endoglin)
|
CD8 expression
|
carotuximab IV (ENV-105)
3years
Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=14, Active, not recruiting, University of Alabama at Birmingham | Trial primary completion date: Aug 2021 --> Dec 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)
over3years
Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=14, Active, not recruiting, University of Alabama at Birmingham | Trial primary completion date: Aug 2020 --> Aug 2021
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)
over3years
The Role of Endoglin in Hepatocellular Carcinoma. (PubMed, Int J Mol Sci)
TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.
Review • Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • ENG (Endoglin)
|
sorafenib • carotuximab IV (ENV-105)
over3years
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). (PubMed, Oncologist)
The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.
Clinical • Journal
|
ENG (Endoglin)
|
Inlyta (axitinib) • carotuximab IV (ENV-105)
over4years
Targeting endoglin expressing regulatory T cells in the tumor microenvironment enhances the effect of PD1 checkpoint inhibitor immunotherapy. (PubMed, Clin Cancer Res)
Taken together these data provide a rationale for combining TRC105 and anti-PD1 therapy and provide additional evidence of endoglin's immunomodulatory role.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
carotuximab IV (ENV-105)
over4years
Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=14, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting | N=35 --> 14 | Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Aug 2020
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
everolimus • letrozole • carotuximab IV (ENV-105)